Skip to main content

Osteoporosis Screening Rates Low for Asian American Medicare Beneficiaries

Medically reviewed by Carmen Pope, BPharm. Last updated on May 1, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, May 1, 2024 -- Rates of dual-energy X-ray absorptiometry (DXA) screening for osteoporosis are lower than expected for Asian American Medicare beneficiaries, according to a study published online March 9 in Skeletal Radiology.

Soterios Gyftopoulos, M.D., from New York University Langone Health in New York City, and colleagues assessed osteoporosis screening utilization rates among Asian American populations. The analysis included 80,439 Medicare beneficiaries.

The researchers found that 15.1 percent received osteoporosis screening. For women, the DXA rate was approximately four times greater than the rate for men (19.8 versus 5.0 percent). For Asian American beneficiaries living in ZIP codes with higher mean household income, DXA was significantly more common than for those in lower-income areas (17.6 versus 14.3 percent). DXA was significantly more common among beneficiaries aged younger than 80 years (15.5 percent) versus those aged 80 years and older (14.1 percent). Asian American beneficiaries had significantly lower DXA rates compared with other races and ethnicities, when controlling for years of Medicare eligibility, age, sex, location, and mean income.

"We found lower than expected DXA screening rates for Asian American patients," the authors write. "A better understanding of the barriers and facilitators to Asian American osteoporosis screening is needed to improve patient care."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

Read this next

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care

TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.